---
title: "Erasca, Inc. (ERAS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ERAS.US.md"
symbol: "ERAS.US"
name: "Erasca, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:26:00.236Z"
locales:
  - [en](https://longbridge.com/en/quote/ERAS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ERAS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ERAS.US.md)
---

# Erasca, Inc. (ERAS.US)

## Company Overview

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.erasca.com](https://www.erasca.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.52 | 465 | - | - | - |
| PB | 8.11 | 379 | 10.69 | 2.25 | 1.10 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 2 | 20% |
| Hold | 1 | 10% |
| Underweight | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.32 |
| Highest Target | 30.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ERAS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ERAS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ERAS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ERAS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**